HETLIOZ
Live / Registered — Registered (as of 03 Aug 2021)
What this means for you
Registered since 03 Aug 2021. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88981892
- Registration number
- 6442600
- Mark type
- Stylized text
- Filed
- 01 Apr 2019
- Published for opposition
- 17 Dec 2019
- Registered
- 03 Aug 2021
- Attorney of record
- Jayme M. Torelli
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, containing tasimelteon, for use in the treatment of circadian rhythm diseases and disorders; pharmaceutical preparations, containing tasimelteon, for use in the treatment of non-24 hour sleep-wake disorder; and pharmaceutical preparations containing tasimelteon for use in the treatment of circadian rhythm sleep disorders; pharmaceutical preparations containing tasimelteon for use in the treatment of Smith-Magenis Syndrome
Owner
- Vanda Pharmaceuticals Inc., Washington, DC, US
- Vanda Pharmaceuticals Inc., Washington, DC, US
- Vanda Pharmaceuticals Inc., Washington, DC, US
Prior registrations
Prosecution history
- 03 Aug 2021 — REGISTERED-PRINCIPAL REGISTER
- 26 Jun 2021 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 25 Jun 2021 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 03 Jun 2021 — STATEMENT OF USE PROCESSING COMPLETE
- 25 Jan 2021 — USE AMENDMENT FILED
- 03 Jun 2021 — DIVISIONAL PROCESSING COMPLETE
- 25 Jan 2021 — DIVISIONAL REQUEST RECEIVED
- 01 Jun 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 10 Feb 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 25 Jan 2021 — TEAS REQUEST TO DIVIDE RECEIVED
- 25 Jan 2021 — TEAS STATEMENT OF USE RECEIVED
- 20 Oct 2020 — ASSIGNED TO EXAMINER
- 18 Jul 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Jul 2020 — SOU EXTENSION 1 GRANTED
- 16 Jul 2020 — SOU EXTENSION 1 FILED